| abstract |
The invention relates to the field of medical technology, in particular to the application of hsa_circRNA_103554 in the diagnosis of retinopathy of prematurity. The present invention proves through research that the level of hsa_circRNA_103554 in patients with retinopathy of prematurity is reduced, which is significantly different from that of normal controls, and can be clinically used as a biomarker for diagnosing retinopathy of prematurity for the diagnosis and differential diagnosis of patients with retinopathy of prematurity. Moreover, down-regulation of hsa_circRNA_103554 level can build a model of retinopathy of prematurity. |